Beneficial effects of co-administration of catechol-O-methyltransferase
inhibitors and L-dihydroxyphenylalanine in rat models of depression
by
Mannisto PT, Lang A, Rauhala P, Vasar E.
Eur J Pharmacol. 1995 Feb 14;274(1-3):229-33

ABSTRACT

The administration of catechol-O-methyltransferase inhibitors alone changed neither the behavior of the rats in two animal models of depression, the forced swimming test (entacapone and tolcapone) or in the learned helplessness paradigm (tolcapone), nor the locomotor activity. L-Dihydroxyphenylalanine (L-DOPA) and carbidopa treatment as such decreased motility but did not improve the behavior in the antidepressant tests. Co-administration of catechol-O-methyltransferase inhibitors and L-DOPA/carbidopa increased the performance of rats in both tests without increasing locomotor activity. Catechol-O-methyltransferase inhibitors could be beneficial as adjunct drugs of L-DOPA not only in Parkinson's disease but also in the coincident depressive illness.

SAMe
COMT
Piribedil
Levodopa
Selegiline
Roxindole
Amineptine
Nomifensine
Pramipexole
Methylphenidate
Tranylcypromine
Parkinson's disease
Mucuna Pruriens and l-dopa
Tolcapone and Parkinson's Disease
Hedonistic homeostatic dysregulation
Tolcapone (Tasmar) as an antidepressant

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family